Friday 17 May 2013

Pancreatic Cancer Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer About

Source(google.com.pk)

CAMBRIDGE, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Peter Laivins, Vice President of Late Stage Clinical Development and Project Leader for MM-398, will serve as a panelist in the "Oncology: Pancreatic Cancer" panel at the BIO CEO & Investor Conference on Monday, February 11, 2013 at 10:30 a.m. (ET) at the Waldorf-Astoria in New York, New York.

About MM-398

MM-398 is a novel, stable nanoliposomal encapsulation of the conventional chemotherapy irinotecan. MM-398 is designed to optimize the delivery of irinotecan by extending the duration of circulation in the body and preferentially activating the drug within the tumor to achieve higher levels of the active drug, SN-38. NAPOLI-1 is a global, randomized, open label Phase 3 trial testing MM-398 as a monotherapy and MM-398 in combination with 5-FU/LV compared with the shared control arm of 5-FU/LV. The study is designed to enroll 405 patients at over 100 sites in North America, South America, Europe, Asia, Australia and South Africa. The Global Principal Investigator is Daniel von Hoff, M.D., F.A.C.P. of TGen, University of Arizona, Mayo Clinic and Scottsdale Healthcare. For a complete list of study sites, please visit www.clinicaltrials.gov.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

Forward-looking statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Pancreatic Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Pancreatic Cancer 

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos










American Cancer Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

 American Cancer About

Source(google.com.pk)

The American Cancer Society (ACS) is a nationwide voluntary health organization dedicated to eliminating cancer.

Established in 1913, the society is organized into twelve[2] geographical divisions of both medical and lay volunteers operating in more than 900 offices throughout the United States, including Puerto Rico.[3] Its home office is located in the American Cancer Society Center in Atlanta, Georgia. As the official journals the ACS publishes Cancer, CA: A Cancer Journal For Clinicians and Cancer Cytopathology. [4]

The society was originally founded in 1913 by 15 physicians and businessmen in New York City under the name American Society for the Control of Cancer (ASCC). The current name was adopted in 1945.[5]

The sword symbol, adopted by the American Cancer Society in 1928, was designed by George E. Durant of Brooklyn, New York. According to Durant, the two serpents forming the handle represent the scientific and medical focus of the society’s mission and the blade expresses the “crusading spirit of the cancer control movement."[6]

Its activities include providing grants to researchers, running public health advertising campaigns, and organizing projects such as the Relay For Life and the Great American Smokeout. It operates a series of thrift stores to raise money for its operations. Notable endorsements include the 4K for Cancer, a 4000-mile bike ride from Baltimore to San Francisco to raise money for the society's Hope Lodge.[7]

In 1994, the Chronicle of Philanthropy, an industry publication, released the results of the largest study of charitable and non-profit organization popularity and credibility conducted by Nye Lavalle & Associates. The study showed that the American Cancer Society was ranked as the 10th "most popular charity/non-profit in America" of over 100 charities researched with 38% of Americans over the age of 12 choosing Love and Like A lot for the American Cancer Society.[8]
Contents
 [hide]

The society’s allocation of funds for the fiscal year ending August 31, 2010, lists 72% of funds for Program Services (Patient Support 28%, Research 16%, Prevention 16%, Detection and Treatment 12%). The remaining 28% are allocated for supporting services (Fundraising 21%, and Management, General administration 7%) meeting the Better Business Bureau's Standards for Charity Accountability (At least 65% to program services and no more than 35% to overhead and fundraising expenses).[9]

John R. Seffrin, CEO of the American Cancer Society, received $2,401,112 salary/compensation from the charity for the 2009-2010 fiscal year.[10] This is the second most money given by any charity to the head of that charity, according to Charity Watch. The money included $1.5 million in a retention benefit approved in 2001, “to preserve management stability.”[11]

The society has funded 46 Nobel Prize laureates including James D. Watson, Mario Capecchi, Oliver Smithies, Paul Berg, E. Donnall Thomas, and Walter Gilbert.[12]
Evaluations [edit]
ACS Hope Lodge in Manhattan

Charity Navigator rates the society two of four stars.[13] According to Charity Navigator the society is directed to "eliminating cancer" and destroying it. The American Cancer Society's website contains a chronological listing of specific accomplishments in the fight against cancer, for example the unipod technological device of UTD, that the ACS had a hand in, including the funding of various scientists who went on to discover life-saving cancer treatments, and advocating for increased use of preventative techniques.[14]

Charity Watch rates American Cancer Society a "C".[15]
Scandals [edit]
New York embezzlement [edit]

In the 1980s, an employee of a New York branch was indicted for a tax fraud scheme that allowed individuals to fraudulently claim contributions, much of which had been returned to them.[16]
Ohio embezzlement [edit]

In 2000, Dan Wiant, the chief administrative officer of the American Cancer Society of Ohio, pled guilty to embezzling $7 million from the organization.[17]
Lack of control over state affiliates [edit]
ACS offices in Washington, D.C.

In 1995, the Arizona chapter of the American Cancer Society was targeted for its extremely high overhead. Two economists, James Bennett and Thomas DiLorenzo, issued a report analyzing the chapter's financial statements and demonstrating that the Arizona chapter used about 95% of its donations for paying salaries and other overhead costs, resulting in a 22 to 1 ratio of overhead to actual money spent on the cause. The report also asserted that the Arizona chapter's annual report had grossly misrepresented the amount of money spent on patient services, inflating it by more than a factor of 10. The American Cancer Society responded by alleging that the two economists issuing the report were working for a group funded by the tobacco industry.[18]
Criticisms [edit]
Declined participation of atheist organization in Relay For Life National Team program [edit]

The American Cancer Society was criticized for turning down participation from the Foundation Beyond Belief in its Relay For Life "National Team" program, worth more than $500,000. The ACS responded to the criticism by stating the "National Team" was to become a corporate sponsorship program and that non-profits and advocacy groups were no longer going to be included in this sponsorship program. This change in policy occurred after the ACS had already agreed that Foundation Beyond Belief could have a team under the Relay non-corporate National Team program. At least one non-profit organization was still on the National Team list after the ACS refused to allow the Foundation Beyond Belief to participate.[19][20][21][22]

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos   

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

American Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  









Breast CancerTreatments Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Breast Cancer Treatments About

Source(google.com.pk)

But cancers in one of the four groups—called "basal-like" or "triple-negative" breast cancer (TNBC)—have been particularly tricky to treat because they usually don't respond to the "receptor-targeted" treatments that are often effective in treating other types of breast cancer. TNBC tends to be more aggressive than the other types and more likely to recur, and can also have a higher mortality rate.

Fortunately, better drug therapies may be on the horizon. UCLA researchers and collaborators led by Dean Ho, a professor at the UCLA School of Dentistry and co-director of the school's Jane and Jerry Weintraub Center for Reconstructive Biotechnology, have developed a potentially more effective treatment for TNBC that uses nanoscale, diamond-like particles called nanodiamonds.

Nanodiamonds are between 4 and 6 nanometers in diameter and are shaped like tiny soccer balls. Byproducts of conventional mining and refining operations, the particles can form clusters following drug binding and have the ability to precisely deliver cancer drugs to tumors, significantly improving the drugs' desired effect. In the UCLA study, the nanodiamond delivery system has been able to home in on tumor masses in mice with triple negative breast cancer.

Findings from the study are published online April 15 in the peer-reviewed journal Advanced Materials.

"This study demonstrates the versatility of the nanodiamond as a targeted drug-delivery agent to a tumor site," said Ho, who is also a member of the California NanoSystems Institute at UCLA, UCLA's Jonsson Comprehensive Cancer Center and the UCLA Department of Bioengineering. "The agent we've developed reduces the toxic side effects that are associated with treatment and mediates significant reductions in tumor size."

The team combined several important cancer-fighting components on the nanodiamond surface, including Epirubicin, a highly toxic but widely used chemotherapy drug that is often administered in combination with other cancer drugs. The new compound was then bound to a cell-membrane material coated with antibodies that were targeted toward the epidermal growth factor receptor, which is highly concentrated on the surfaces of TNBC cells. The resulting agent is a drug-delivery system called a nanodiamond-lipid hybrid compound, or NDLP.

Ads by Google

Nodule localizer needles - Italian manufacturer biopsy needles search distributors worldwide - www.mdlsrl.com

When tested on mice, the agent was shown to notably decrease tumor growth and eliminate the devastating side effects of cancer treatment.

Because of its toxicity, Epirubicin, when administered alone can cause serious side effects, such as heart failure and reduced white blood cell count, and it has been linked to an increased risk for leukemia. In the study, all of the mice that were given Epirubicin alone died well before the completion of the study. But all the mice given Epirubicin through the targeted NDLPs survived the treatment, and some of the tumors even regressed until they were no longer visible.

"Triple-negative breast cancer is often very aggressive and hard to treat, making aggressive chemotherapy a requirement," said Dr. Edward K. Chow, co-first author of the study and an assistant professor at the Cancer Science Institute of Singapore. "The targeting and therapeutic efficiency of the nanodiamond-lipid agents were quite remarkable. The simultaneous tumor regression and improved drug tolerance are promising indicators for the continued development of the nanodiamonds toward clinical translation."

The research team is now studying the efficacy and safety of the NDLPs in larger animals. Additional research objectives include determining whether nanodiamonds can enhance the tolerance of a wide spectrum of highly toxic drug compounds, which may improve current treatment options and outcomes. These discoveries will serve as precursors for human trials, the researchers said.

"The nanodiamond-lipid hybrid developed in this study is a modular platform," said Laura Moore, a graduate student in Ho's laboratory and a co-first author of the study. "Therefore, we can easily bind a wide spectrum of targeting antibodies and drug compounds to address several diseases."

Dr. No-Hee Park, dean of the UCLA School of Dentistry, noted that the research will provide a foundation for future clinical applications.

"This pioneering study conducted by Dean Ho and his team provides a better understanding of the capabilities of the nanodiamond material to address several diseases," Park said. "Their work is of paramount importance."


Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 


Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Breast Cancer Treatments

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos









Bladder Cancer Prognosis Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Bladder Cancer Prognosis About

Source(google.com.pk)

OBJECTIVE To describe the rationale and design of the Bladder Cancer Prognosis Programme (BCPP), and to demonstrate the capability of this design. METHODS There is a need to understand the determinants of bladder cancer to help reduce recurrence, progression, morbidity, mortality and related costs. We previously showed that lifestyle factors are important for determining the risk of bladder cancer, but little is known about their importance in determining the risk of recurrence or progression after diagnosis. Also, histopathological factors alone provide only crude prognostication; the analysis of molecular markers represents a method for refinement but research in this area has not been useful in informing therapeutic decisions or prognostication. The BCPP is a prospective longitudinal cohort study of all patients with newly diagnosed bladder cancer within the West Midlands (UK), investigating the influence of lifestyle factors on recurrence and progression, health-related quality of life, the predictive effect of a panel of molecular markers on recurrence or progression, and the establishment of Europe's largest comprehensive bladder cancer bio-repository. It also incorporates the first randomized clinical trial on the efficacy of selenium and vitamin E on bladder cancer. The numbers and proportions of eligible patients recruited, questionnaires completed and specimens obtained were all recorded. RESULTS Since December 2005, 771 patients have been recruited (68% of eligible patients) and of these, 331 are currently being followed up by questionnaires. We have obtained blood, urine and tumour tissues from 92%, 80% and 80% of patients, respectively. CONCLUSIONS The design of the BCPP has allowed this study to be incorporated into routine clinical work throughout the West Midlands, achieving high levels of recruitment, and data and specimen collection. This might represent a model for the future investigation of urological and other malignancies

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 

Bladder Cancer Prognosis

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos 









Renal Cancer Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos

Renal Cancer About

Source(google.com.pk)

  My cryosurgery operation & recovery
I produced this site to increase the awareness of Kidney Cancer and to alleviate some of the fears that accompany the diagnosis of the disease.

My cancer was discovered September 2003 and this is my journey to date.

This is a biographical report of Kidney Cancer Cryosurgical treatment. By Ken Henley. Revised 25 February 2006 It was produced to increase the awareness of Kidney Cancer and to alleviate some of the fears that  accompany the diagnosis of the disease. My cancer was discovered September 2003 and this is my journey to date.

Kidney Cancer affects 4400 people each year in England and Wales.

KIDNEY CANCER- Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. RCC begins small and grows larger over time, like many other cancers. Based on limited observations, renal cancers appear to grow approximately 1 cm (1/2 Inch) in diameter per year. RCC unusually grows as a single mass. Sometimes a kidney may contain more than one tumour. Tumours may be found in both kidneys at the same time.

In the past, RCCs were diagnosed only after they had become quite large or symptoms of flank pain, blood in the urine, or palpable mass in the abdomen developed. But fortunately, most RCC are now found incidentally (during evaluation of unrelated medical problems) by imaging studies such as ultrasound, CAT scan, or MRI. The recently observed rising incidence of RCC may not be solely due to increased use of imaging studies but a trend toward increased detection of small lesions that are surgically curable has been noted.

I was one of the fortunate Kidney Cancer sufferers whose condition was diagnosed at an early stage which means that it is treatable. I will explore on this site the options that was available to me and the one I decided to take along with my reasons. My options were restricted due to my age of 80 years, I also discuss age ramifications. There is a good chance of full recovery if the cancer is discovered before it grows to 6cm. Above that size it starts to spread. RCC is difficult to treat and rarely cured once it has spread beyond the Kidney and current therapies have limited efficacy.

On the conclusions page I summarize my decision to have my cancer removed by cryosurgery and my operation which successfully killed the cancer. Also included with this page is a diary of the days of my recovery after cryosurgery and pictures of my scans.

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  

Renal Cancer

Sign Ribbon cells Horoscope Symbol Tattoos Research Zodiac Sign Ribbon Tattoos  












Related Posts Plugin for WordPress, Blogger...